Incyte Corp. (INCY)

Company Description

Incyte Corporation (Wilmington, Delaware) is a biopharmaceutical company that is focused on developing novel small molecule therapies for the treatments of cancers and inflammatory diseases. The company obtained approval in the U.S. for Jakafi in late 2011, which is a first-in class compound for myeloproliferative disorders that inhibits the intraceullar Janus kinases (Jak) signaling pathway; the ex-U.S. ruxolitinib rights have been licensed to Novartis in a deal potentially valued at up to $1 billion. INCY’s second key pipeline product is INCB28050, which is a second-generation oral Jak inhibitor in development for autoimmune disorders such as rheumatoid arthritis. The company has licensed global rights to INCB28050 to Lilly, and plans to co-develop the agent in rheumatoid arthritis. Behind ruxolitinib and INCB28050, INCY has several earlierstage Phase I/II oncology assets, which have different mechanisms of action, and a fully owned second generation Jakafi.

 

COMPANY ADDRESS
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States

COMPANY PHONE
302-498-6700

COMPANY WEBSITE



Get BioInvest's perspective on Incyte's CEO


Latest Company News

These stock's have rarely let down their investors: Incyte Corporation (INCY ... StockNewsJournal - 2 hours ago Incyte Corporation (NASDAQ:INCY) market capitalization at present is $27.24B at the rate of $134.67 a share. The firm's price-to-sales ratio was noted 22.76 in contrast with an overall industry average of 111.84. Challenges And Opportunities For Incyte Corporation (INCY), SunPower ... - AllStockNews [...]
Tue, Jun 27, 2017 7:40:00 PM, Continue reading at the source
Incyte Corporation (INCY) Getting Favorable Media Coverage, Report Shows Sports Perspectives - 5 hours ago Incyte Corporation logo Media headlines about Incyte Corporation (NASDAQ:INCY) have trended positive recently, according to Accern Sentiment Analysis. Clough Capital Partners LP Buys Shares of 5900 Incyte Corporation (INCY) - BNB Daily (blog) Teachers Retirement System of The State of Kentucky Buys New Stake in Incyte ... - The Cerbat Gem [...]
Tue, Jun 27, 2017 4:30:00 PM, Continue reading at the source
Investors Are Circling Incyte Corporation (NasdaqGS:INCY), What Do the Numbers ... Stock Talker - 12 hours ago The Shareholder Yield of Incyte Corporation (NasdaqGS:INCY) is -8.88%. The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share repurchases and debt ... [...]
Tue, Jun 27, 2017 9:33:00 AM, Continue reading at the source
Price Alert: Incyte Corporation (NASDAQ:INCY) Stock Nears Resistance ... CML News - Jun 24, 2017 Price Alert: Incyte Corporation (NASDAQ:INCY) has now crossed into technical strength -- watch the technical oscillators for momentum gaps. [...]
Sat, Jun 24, 2017 5:26:00 PM, Continue reading at the source
Risk Malaise Alert in Option Market: Incyte Corporation Implied Price Swing ... CML News - Jun 23, 2017 Before we dive into any analysis we simply note that Incyte Corporation (NASDAQ:INCY) risk is actually priced pretty low by the option market as of right now. [...]
Fri, Jun 23, 2017 4:18:00 PM, Continue reading at the source
Lookout for Price Target? Incyte Corporation (INCY), Halozyme Therapeutics ... StockNewsJournal - Jun 21, 2017 Incyte Corporation (INCY) have shown a high EPS growth of 18.70% in the last 5 years and has earnings decline of -238.90% yoy. [...]
Wed, Jun 21, 2017 3:56:00 PM, Continue reading at the source
Incyte Corporation (NASDAQ:INCY) Short Interest Up by 19.82% – Shares Trading Down Highlight Press - Jun 19, 2017 Short traders are more bearish on shares of Incyte Corporation recently as inferred by the uptick in short interest. The company realized a rise in short interest from May 31, 2017 to May 15, 2017 of 19.82%. Investors are upbeat on the prospect of these stock's: Incyte Corporation ... - StockNewsJournal Incyte Corporation (INCY) And Its Technical Chart Is On Show - NY Stock News [...]
Mon, Jun 19, 2017 11:03:00 AM, Continue reading at the source
Incyte (INCY) Up 3.4% Since Earnings Report: Can It Continue? Nasdaq - Jun 9, 2017 It has been about a month since the last earnings report for Incyte Corporation INCY . Shares have added about 3.4% in that time frame, outperforming the market. Why Investors remained buoyant on: Ambarella, Inc. (AMBA), Incyte Corporation ... - StockNewsJournal How Technical Charts Are Flashing For Incyte Corporation (INCY), Harte Hanks ... - Post Analyst [...]
Fri, Jun 09, 2017 8:37:00 AM, Continue reading at the source
3 Takeaways From Monday's ASCO Meetings: Puma Biotech, Incyte, Celgene Benzinga - Jun 6, 2017 The event was filled with updates on clinical trials and research. Credit Suisse analyst Alethia Young released her key findings from Monday's session regarding Puma Biotechnology Inc (NASDAQ: PBYI), Incyte Corporation (NASDAQ: INCY) and Celgene ... [...]
Tue, Jun 06, 2017 8:39:00 PM, Continue reading at the source
Incyte's epacadostat data OK - Barclays Seeking Alpha - Jun 5, 2017 Incyte (NASDAQ:INCY) is up a fraction after hours after slipping almost 6% in the regular session. The sell-off was stoked by report by TheStreet's Adam Feuerstein who noted that several patient responders were missing in the latest data on the ... Why Herbalife Ltd. (HLF), Snap Inc (SNAP) and Incyte Corporation (INCY) Are 3 ... - Investorplace.com Incyte Announces Data on Enzyme Inhibitor with Keytruda - Yahoo Finance [...]
Mon, Jun 05, 2017 8:48:00 PM, Continue reading at the source